Alopecia Areata Clinical Trials 2022

Browse 48 Alopecia Areata Medical Studies Across 165 Cities

4 Phase 3 Trial · 359 Alopecia Areata Clinics

Clinical TrialsAlopecia Areata Clinical Trials 2022
Reviewed by Michael Gill, B. Sc.
Photo of icahn school of medicine at mount sinai 1
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Dupilumabfor Alopecia Areata

New York, NY
18+
All Sexes
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of atopy. Subjects will be randomized (2:1) to either receive weekly dupilumab or placebo for 48 weeks, with all subjects completing participation through Week 48 receiving an additional 48 weeks of dupilumab (through Week 96).
Phase 2
Waitlist Available
Photo of maryland 1
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Ruxolitinibfor Alopecia Areata

Bethesda, MD
Any Age
All Sexes
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved to treat AA. Objective: To see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body. Eligibility: People aged 12 to 65 years with APECED and severe AA. Design: Participants will be in this study for up to 10 months. They will have 5 in-person visits and 6 televisits, each about 4 weeks apart. One in-person visit may be up to a 10-day stay in the hospital. The first in-person visit will include screening. Participants will have a physical exam. They will have blood tests. Photographs may be taken of their skin. They will answer questions about their quality of life. Participants will begin taking the study drug during their hospital stay. They will take the pills by mouth twice a day for 8 months. Researchers may take tissue samples from participants scalp, gums, and lower lip. Participants may provide samples of urine, stool, nail clippings, and saliva. They may have an eye exam and an ultrasound exam of their abdomen. Some tests may be repeated in subsequent in-person visits. In telehealth visits, participants will answer questions about how they are feeling. They will describe and send photos of hair regrowth. They will be asked to have blood drawn and the results sent to the researchers.
Phase 2
Recruiting
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Alopecia Areatafor Alopecia Areata

Winston-Salem, NC
18+
All Sexes
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions. Psoriasis is one of the most common conditions treated with phototherapy, in which phototherapy is often indicated for extensive disease with contraindications for other systemic treatments. The mechanism of action of phototherapy for the treatment of psoriasis is not completely understood; however, it is known that UVB light induces apoptosis of pathogenic T cells and keratinocytes, which may reduce the overactive immune response and epidermal hyperproliferation. Phototherapy has shown some efficacy for other diseases, such as alopecia areata (AA) and polymorphous light eruption (PMLE). However, phototherapy is not always an accessible treatment option for patients due to cost or lack of time.
Recruiting
Has No Placebo
Photo of aurora 1
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Tofacitinibfor Hidradenitis Suppurativa

Aurora, CO
< 65
All Sexes
This trial tests if a drug that blocks interferon signaling is safe and effective in people with Down syndrome and an autoimmune or autoinflammatory skin condition. The primary purpose of this clinical trial is to evaluate the safety and efficacy of On Treatment for Hidradenitis Suppurativa. The trial will enroll approximately 300 participants.This clinical trial is evaluating the safety and efficacy of On Treatment for Hidradenitis Suppurativa. On Treatment has previously been approved by the FDA for a different condition. The trial will enroll approximately 300 participants and will not include a placebo group.
Phase 2
Recruiting
Photo of icahn school of medicine at mount sinai 1
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

PF-06651600for Cicatricial Alopecia

New York, NY
18+
All Sexes
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The research team will be administering a new investigational drug (a JAK3/TEC inhibitor), ritlecitinib, which has shown statistically significant improvement in scalp hair loss for AA patients in a proof of concept and phase 2b/3 studies (B7981015 AA study). This is an open-label clinical trial. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.
Phase 2
Waitlist Available
25 Alopecia Areata Clinical Trials Near Me
New York, NY
Rochester, NY
Houston, TX
Bethesda, MD
More Trial Locations
An interactive map to display trial locations for Icahn School of Medicine at Mount Sinai, UR Dermatology at College Town, The University of Texas Health Science Center at Houston, National Institutes of Health Clinical Center, and 243 more locations.
Most Popular References for Alopecia Areata Clinical Trials
Frequency
Citation
7
Zhao, Yong, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, et al.. 2012. “Reversal of Type 1 Diabetes via Islet Β Cell Regeneration Following Immune Modulation by Cord Blood-derived Multipotent Stem Cells”. BMC Medicine. Springer Science and Business Media LLC. doi:10.1186/1741-7015-10-3.
6
Zhu, Min, Zhengyu Zhou, Yan Chen, Ronda Schreiber, John T. Ransom, John K. Fraser, Marc H. Hedrick, Kai Pinkernell, and Hai-Chien Kuo. 2010. “Supplementation of Fat Grafts with Adipose-derived Regenerative Cells Improves Long-term Graft Retention”. Annals of Plastic Surgery. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/sap.0b013e31819ae05c.
6
Zhao, Yong. 2012. “Stem Cell Educator Therapy and Induction of Immune Balance”. Current Diabetes Reports. Springer Science and Business Media LLC. doi:10.1007/s11892-012-0308-1.
5
Sullivan, T, J Smith, J Kermode, E Mclver, and D J Courtemanche. 1990. “Rating the Burn Scar”. Journal of Burn Care & Rehabilitation. Oxford University Press (OUP). doi:10.1097/00004630-199005000-00014.
4
Alexander, Robert, and David Harrell. 2013. “Autologous Fat Grafting: Use of Closed Syringe Microcannula System for Enhanced Autologous Structural Grafting”. Clinical, Cosmetic and Investigational Dermatology. Informa UK Limited. doi:10.2147/ccid.s40575.
3
Vaccaro M, Cannavò SP, Imbesi S, Cristani M, Barbuzza O, Tigano V, Gangemi S. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo. Int J Dermatol. 2015 Jun;54(6):672-4. doi: 10.1111/ijd.12392. Epub 2014 Nov 27.
3
NORWOOD, OʼTAR T.. 1975. “Male Pattern Baldness: Classification and Incidence”. Southern Medical Journal. Southern Medical Association. doi:10.1097/00007611-197511000-00009.
3
Alexander, Robert W.. 2016. “Biocellular Regenerative Medicine”. Physical Medicine and Rehabilitation Clinics of North America. Elsevier BV. doi:10.1016/j.pmr.2016.06.005.
3
Li, Yanjia, Baoyong Yan, Hepeng Wang, Heng Li, Quanhai Li, Dong Zhao, Yana Chen, et al.. 2015. “Hair Regrowth in Alopecia Areata Patients Following Stem Cell Educator Therapy”. BMC Medicine. Springer Science and Business Media LLC. doi:10.1186/s12916-015-0331-6.
3
Toyokawa, Hideyoshi, Yoichi Matsui, Junya Uhara, Hideto Tsuchiya, Shigeru Teshima, Hideki Nakanishi, A-Hon Kwon, et al.. 2003. “Promotive Effects of Far-infrared Ray on Full-thickness Skin Wound Healing in Rats”. Experimental Biology and Medicine. SAGE Publications. doi:10.1177/153537020322800612.
Top Hospitals for Alopecia Areata Clinical Trials
Location
Active Alopecia Areata Clinical Trials
All Time Trials for Alopecia Areata
First Recorded Alopecia Areata Trial
Trials
Icahn School of Medicine at Mount Sinai, New York, New York
5
14
2015
Dupilumab for Alopecia Areata
, CTP-543 for Alopecia Areata
, PF-06651600 for Cicatricial Alopecia ... View More
California Dermatology & Clinical Research Institute, Encinitas, California
4
6
2018
CTP-543 for Alopecia Areata
, Etrasimod for Alopecia Areata
, CTP-543 for Alopecia Areata ... View More
University of California, Irvine, Irvine, California
4
5
2017
CTP-543 for Alopecia Areata
, Etrasimod for Alopecia Areata
, PF-06651600 for Alopecia Areata ... View More
Investigate MD, Scottsdale, Arizona
3
3
2019
Daxdilimab for Alopecia Areata
, Etrasimod for Alopecia Areata
, Baricitinib for Alopecia Areata
First OC Dermatology, Fountain Valley, California
3
4
2018
Daxdilimab for Alopecia Areata
, Etrasimod for Alopecia Areata
, Baricitinib for Alopecia Areata
Top Treatments for Alopecia Areata Clinical Trials
Treatment Name
Active Alopecia Areata Clinical Trials
All Time Trials for Alopecia Areata
First Recorded Alopecia Areata Trial
Trials
PF-06651600
3
4
2016
PF-06651600 for Alopecia Areata
, PF-06651600 for Alopecia Areata
, PF-06651600 for Cicatricial Alopecia
CTP-543
2
4
2017
CTP-543 for Alopecia Areata
, CTP-543 for Alopecia Areata
Baricitinib
2
2
2018
Baricitinib for Alopecia Areata
, Baricitinib for Alopecia Areata
Laser
2
2
2018
Laser for Alopecia
, Laser for Alopecia Areata
Dupilumab
1
2
2018
Dupilumab for Alopecia Areata
Top Cities for Alopecia Areata Clinical Trials
City
Active Alopecia Areata Clinical Trials
Top Active Site for Alopecia Areata Clinical Trials
Trial List
New York, New York
10
Icahn School of Medicine at Mount Sinai
Dupilumab for Alopecia Areata
, Rosnilimab for Alopecia Areata
, Etrasimod for Alopecia Areata ... View More
Houston, Texas
9
Suzanne Bruce and Associates, PA
SADBE 5% for Alopecia Areata
, Rosnilimab for Alopecia Areata
, CTP-543 for Alopecia Areata ... View More
San Antonio, Texas
9
Progressive Clinical Research
Daxdilimab for Alopecia Areata
, Rosnilimab for Alopecia Areata
, Etrasimod for Alopecia Areata ... View More
Portland, Oregon
9
NW Dermatology Institute
CTP-543 for Alopecia Areata
, Etrasimod for Alopecia Areata
, Baricitinib for Alopecia Areata ... View More
Minneapolis, Minnesota
8
University of Minnesota Department of Dermatology
CTP-543 for Alopecia Areata
, PF-06651600 for Alopecia Areata
, PF-06651600 for Alopecia Areata ... View More
Which phases are most popular for alopecia areata clinical trials?
Phase
Active Alopecia Areata Clinical Trials
Number of Unique Treatments
Number of Active Locations
Trial List
Phase < 1
9
9
2
SADBE 5% for Alopecia Areata
, oral minoxidil for Alopecia
, Laser for Alopecia Areata ... View More
Phase 1
1
1
2
TDM-105795 for Androgenetic Alopecia
Phase 2
17
16
107
Dupilumab for Alopecia Areata
, Ruxolitinib for Alopecia Areata
, Daxdilimab for Alopecia Areata ... View More
Phase 2 & 3
2
2
90
CTP-543 for Alopecia Areata
, Baricitinib for Alopecia Areata
Phase 3
2
2
0
PF-06651600 for Alopecia Areata
, Baricitinib for Alopecia Areata
Phase 4
3
3
3
MedJet Device with intralesional triamcinolone for Alopecia Areata
, Topical steroid plus oral antibiotic group for Central Centrifugal Cicatricial Alopecia (CCCA)
, Venus Glow for Alopecia
N/A
14
14
10
Alopecia Areata for Alopecia Areata
, Tattoo machine (SOL Nova Device) for Alopecia Areata
, PRP Concentration for Alopecia Areata ... View More
How many alopecia areata clinical trials are open to youth and / or seniors?
Age Group
Active Alopecia Areata Clinical Trials
Trial List
< 18
1
MedJet Device with intralesional triamcinolone for Alopecia Areata
18+
34
Dupilumab for Alopecia Areata
, Alopecia Areata for Alopecia Areata
, Daxdilimab for Alopecia Areata ... View More
18 - 65
8
PF-06651600 for Alopecia Areata
, Topical steroid plus oral antibiotic group for Central Centrifugal Cicatricial Alopecia (CCCA)
, incobotulinumtoxin A for Androgenetic Alopecia ... View More
< 65
2
SADBE 5% for Alopecia Areata
, Tofacitinib for Hidradenitis Suppurativa
Any Age
3
Ruxolitinib for Alopecia Areata
, PF-06651600 for Alopecia Areata
, Alopecia Assessments for Alopecia
Most Recent Alopecia Areata Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Laser for Alopecia
9/30/2022
Phase 2
Stem Cell Educator therapy combined with minoxidil for Alopecia
9/20/2022
Phase 2
PF-06651600 for Cicatricial Alopecia
9/1/2022
Phase 2
Platelet-rich Plasma Left Side for Androgenetic Alopecia
9/1/2022
Phase < 1
AMMA Portalbe Scalp Cooling System for Breast Cancer
8/15/2022
N/A
Phase 3 Alopecia Areata Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
PF-06651600 for Alopecia Areata
7/18/2019
Phase 3
Baricitinib for Alopecia Areata
7/8/2019
Phase 3
CTP-543 for Alopecia Areata
4/4/2019
Phase 2 & 3
Baricitinib for Alopecia Areata
9/24/2018
Phase 2 & 3
Pediatric Alopecia Areata Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
SADBE 5% for Alopecia Areata
6/15/2022
Phase < 1
MedJet Device with intralesional triamcinolone for Alopecia Areata
3/24/2022
Phase 4
Alopecia Assessments for Alopecia
6/4/2021
N/A
Tofacitinib for Hidradenitis Suppurativa
10/21/2020
Phase 2
PF-06651600 for Alopecia Areata
7/18/2019
Phase 3
Senior Friendly Alopecia Areata Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Laser for Alopecia
9/30/2022
Phase 2
Stem Cell Educator therapy combined with minoxidil for Alopecia
9/20/2022
Phase 2
PF-06651600 for Cicatricial Alopecia
9/1/2022
Phase 2
Platelet-rich Plasma Left Side for Androgenetic Alopecia
9/1/2022
Phase < 1
AMMA Portalbe Scalp Cooling System for Breast Cancer
8/15/2022
N/A
Recently Completed Studies with FDA Approved Treatments for Alopecia Areata
Treatment
Year
Mechanism of Action
Sponsor
Active Alopecia Areata Clinical Trials
CTP-543, 12 mg BID
2021
Concert Pharmaceuticals
0
TDM-105795
2021
Technoderma Medicines Inc.
0
CTP-543, 12 mg BID
2020
Concert Pharmaceuticals
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: August 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Relevant Clinical Trials

Neuropathy Clinical Trials 2022
Peanut Allergy Clinical Trials 2022
Hearing Loss Clinical Trials 2022
IBS Clinical Trials 2022
NASH Clinical Trials 2022
Allergy Clinical Trials 2022
Transcranial Magnetic Stimulation Clinical Trials 2022
Vaccine Clinical Trials 2022
Mental Health Clinical Trials 2022
Epilepsy Clinical Trials 2022
Glaucoma Clinical Trials 2022
Heart Failure Clinical Trials 2022
Migraine Clinical Trials 2022
Osteoporosis Clinical Trials 2022
Pregnancy Clinical Trials 2022
Skin Care Clinical Trials 2022
RA Clinical Trials 2022
Vitiligo Clinical Trials 2022
Gastroparesis Clinical Trials 2022
IPF Clinical Trials 2022

Top Oncology Trials

Cancer Clinical Trials 2022
Pancreas Cancer Clinical Trials 2022
Prostate Cancer Clinical Trials 2022
Breast Cancer Clinical Trials 2022
Oncology Clinical Trials 2022
Pancreatic Cancer Clinical Trials 2022
Colon Cancer Clinical Trials 2022
Lung Cancer Clinical Trials 2022
Melanoma Clinical Trials 2022
Multiple Myeloma Clinical Trials 2022
Ovarian Cancer Clinical Trials 2022
Triple Negative Breast Cancer Clinical Trials 2022
Esophageal Cancer Clinical Trials 2022
CLL Clinical Trials 2022
Small Cell Lung Cancer Clinical Trials 2022
Leukemia Clinical Trials 2022
Mesothelioma Clinical Trials 2022
AML Clinical Trials 2022
Bladder Cancer Clinical Trials 2022
Brain Cancer Clinical Trials 2022

Popular Clinical Trials

COVID Clinical Trials 2022
Depression Clinical Trials 2022
ALS Clinical Trials 2022
Marijuana Clinical Trials 2022
Type 1 Diabetes Clinical Trials 2022
IVF Clinical Trials 2022
PTSD Clinical Trials 2022
Tinnitus Clinical Trials 2022
Diabetes Clinical Trials 2022
Coronavirus Clinical Trials 2022
Lupus Clinical Trials 2022
Psilocybin Clinical Trials 2022
Rheumatoid Arthritis Clinical Trials 2022
Multiple Sclerosis Clinical Trials 2022
Obesity Clinical Trials 2022
Psoriasis Clinical Trials 2022
Alzheimer's Disease Clinical Trials 2022
Asthma Clinical Trials 2022
Lyme Disease Clinical Trials 2022
Osteoarthritis Clinical Trials 2022
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top